LABU241227C128000
- 0.50
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Weekly Buzz: So far, Santa is Letting us Down
Bristol-Myers Squibb's Opdivo Qvantig Gets US FDA Approval
Looking At Amgen's Recent Unusual Options Activity
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Top Dividend Picks for 2025 According to Seeking Alpha's Quant Metrics
10 Health Care Stocks With Whale Alerts In Today's Session
Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Looking Into AbbVie's Recent Short Interest
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Spotlight on Amgen: Analyzing the Surge in Options Activity
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
What's Going On With Amgen Stock On Friday?
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Neurocrine Biosciences Analyst Ratings